Argentina’s national health regulator, ANMAT, has issued two critical directives aimed at safeguarding public health, ranging from the immediate recall of a specialized injectable medication to the permanent shuttering of two pharmaceutical firms. These latest novedades de la ANMAT highlight a rigorous approach to both product quality control and the enforcement of administrative sanctions for systemic regulatory failures.
The first measure involves a voluntary market withdrawal of a specific batch of Calcium Gluconate produced by Lavimar S.A. The action was triggered after the discovery of suspended particulate matter within an ampoule, a defect that can pose significant risks when administered intravenously. Simultaneously, the agency has finalized a long-standing administrative process to permanently revoke the operating licenses of HLB Pharma Group S.A. And Laboratorios Ramallo S.A.
For healthcare providers and patients, these updates underscore the importance of strict lot verification and the necessity of following official traceability protocols for the disposal of prohibited medical supplies. As a board-certified physician, I recognize that particulate contamination in injectable medications is a high-priority safety concern, as it can lead to vascular complications or inflammatory responses in critically ill patients.
Urgent Recall of Calcium Gluconate Lavimar
Lavimar S.A. Has initiated the voluntary removal of Calcium Gluconate 90 mg/ml (injectable) from the market. The regulator has specifically identified lot 25100, which carries an expiration date of June 2028 and is registered under Certificate No. 41368. The product is typically distributed in packages of 100 ampoules of 10 ml each.
This medication is a critical intervention used to treat severe hypocalcemia, neonatal calcium deficiency, or cases of tetany. It is also utilized in the management of severe hyperkalemia to protect the heart from the effects of excess potassium. Due to the fact that this drug is often administered in emergency or intensive care settings, the presence of suspended material—small particles that should not be in a sterile solution—represents a breach of pharmacological purity standards.
ANMAT is currently monitoring the withdrawal process and has explicitly advised the medical community and pharmacy distributors to abstain from using any units belonging to the affected lot. Institutions holding this stock should isolate the product immediately to prevent accidental administration.
Permanent Ban for HLB Pharma and Laboratorios Ramallo
In a more severe regulatory move, ANMAT has concluded the administrative process to permanently revoke the authorizations of HLB Pharma Group S.A. (File No. 7350) and Laboratorios Ramallo S.A. (File No. 7473). This decision, formalized through Disposición Nº 1848/2026, marks the end of a series of escalating sanctions.
The permanent closure follows a history of sanitary summaries, warning letters, and the previous Disposición ANMAT Nº 3158/2025, which had already inhibited the firms’ productive activities and prohibited the sale and distribution of all their products. According to the regulator, the companies failed to capture the necessary corrective actions to lift the previous inhibitions or respond to the warning letters.
The case is further complicated by a judicial investigation. ANMAT has collaborated with the Federal Criminal and Correctional Court No. 3 of La Plata, presided over by Judge Ernesto Kreplak, regarding cause FLP 17371/2025. This legal action is specifically tied to the market recall of fentanyl lots 31202 and 31244.
Interestingly, while the firms’ general authorizations are revoked, the court has ordered that the Certificates of Registration for their medicinal specialties be re-registered and kept active. This represents a legal maneuver to preserve these registries as potential assets of the firms for the duration of the judicial proceedings.
Summary of Regulatory Actions (April 10, 2026)
| Entity/Product | Action Taken | Primary Reason | Reference |
|---|---|---|---|
| Calcium Gluconate (Lavimar) | Lot 25100 Recall | Suspended material in ampoules | Cert. 41368 |
| HLB Pharma Group S.A. | Permanent License Revocation | Regulatory failure / Fentanyl case | Disp. 1848/2026 |
| Laboratorios Ramallo S.A. | Permanent License Revocation | Regulatory failure / Fentanyl case | Disp. 1848/2026 |
Impact on Healthcare Institutions and Traceability
The permanent removal of HLB Pharma and Laboratorios Ramallo from the legal pharmaceutical landscape creates a logistical requirement for hospitals and pharmacies. Institutions that still possess products, supplies, or medications from these firms under the scope of Disposición Nº 3158/2025 must manage their disposal with extreme caution.
The regulator emphasizes that any transfer of these products for destruction or final disposal—provided they are not currently held as evidence in the ongoing judicial case—must strictly adhere to current traceability laws. This ensures that prohibited substances do not leak back into the grey market, particularly concerning high-potency opioids like fentanyl.
These novedades de la ANMAT serve as a reminder that the pharmaceutical supply chain relies on a “chain of trust.” When a manufacturer fails to maintain the purity of a sterile injectable or ignores systemic regulatory warnings, the agency’s role shifts from oversight to enforcement to prevent potential patient morbidity.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Healthcare professionals should refer to the official ANMAT portal for full technical specifications and legal directives.
The next phase of this regulatory cycle will involve the continued monitoring of the Calcium Gluconate recall and the progression of the judicial case in La Plata. Further updates regarding the final disposal of assets from the revoked firms are expected as the court proceedings evolve.
Do you have information regarding these lots or the affected firms? Share this update with your colleagues or leave a comment below to discuss the impact on local healthcare supply.
Worth a look
